A 62-year-old postmenopausal woman from Mumbai presents with postmenopausal bleeding for 2 months. She has no significant past medical history and a normal BMI. Pelvic examination reveals a normal-sized uterus. Transvaginal ultrasound shows an endometrial thickness of 6 mm with a well-circumscribed, polypoid mass. Hysteroscopy and endometrial biopsy reveal a grade 1 endometrioid adenocarcinoma confined to the endometrium (stage IA). Staging MRI shows no myometrial invasion, no cervical involvement, and normal pelvic lymph nodes. What is the most appropriate next step in management?

Explanation

## Management of Early-Stage Endometrial Carcinoma (Stage IA, Grade 1) ### Risk Stratification in Endometrial Carcinoma Endometrial cancer management is guided by histologic grade, myometrial invasion depth, and molecular/genetic factors. This patient has **low-risk disease** and requires minimal adjuvant therapy. **Key Point:** Stage IA, grade 1 endometrioid adenocarcinoma with no myometrial invasion is considered **low-risk** and does NOT require adjuvant radiation or chemotherapy after surgery alone. ### Risk Classification | Risk Category | Criteria | 5-Year Recurrence | Adjuvant Therapy | |---------------|----------|-------------------|------------------| | **Low-risk** | Stage IA, Grade 1–2, endometrioid, no LVSI | <5% | Surgery alone | | **Intermediate-risk** | Stage IB, Grade 1–2 OR Grade 3 + Stage IA | 10–15% | Consider VBT or observation | | **High-risk** | Stage III, Grade 3, non-endometrioid, LVSI | >20% | Chemotherapy ± radiation | **High-Yield:** The presence of **no myometrial invasion** in a **grade 1 tumor** makes this patient ideal for surgery-only management. Adjuvant therapy adds toxicity without survival benefit in this cohort. ### Surgical Approach **Clinical Pearl:** For early-stage endometrial cancer, total hysterectomy with bilateral salpingo-oophorectomy (TH-BSO) is the standard. The route (abdominal, laparoscopic, or robotic) depends on surgeon expertise and patient factors, but all are acceptable for stage IA disease. - **Pelvic lymph node dissection:** NOT routinely required for stage IA, grade 1–2 endometrioid cancers (low risk of nodal metastasis) - **Para-aortic lymph node dissection:** NOT required for low-risk disease ### Why Adjuvant Therapy Is Not Indicated 1. **No myometrial invasion** → very low risk of occult nodal disease 2. **Grade 1 histology** → favorable biology 3. **Endometrioid type** → better prognosis than serous or clear-cell 4. **5-year recurrence rate <5%** with surgery alone **Warning:** Do not over-treat low-risk endometrial cancer. Adjuvant radiation increases morbidity (bowel toxicity, sexual dysfunction) without improving overall survival in this population. ### Rationale Against Other Options - **Adjuvant external beam radiation (EBRT):** Indicated for intermediate-risk (stage IB, grade 3) or high-risk disease. Not needed for stage IA, grade 1. - **Neoadjuvant chemotherapy:** Reserved for advanced (stage III–IV) or non-endometrioid (serous, clear-cell) histology. - **Brachytherapy:** Considered for intermediate-risk disease; not standard for low-risk stage IA. [cite:Robbins 10e Ch 22]